Abstracts

Rationale: Eslicarbazepine (ESL) constitutes an antiepileptic drug approved as add-on treatment for partial-onset seizures with or without secondary generalization. We aim to analyze our experience according to daily clinical practice in Galicia, Spain. Methods: We performed a multicentric observational retrospective study of ESL used as treatment for focal seizures from June 2014 to June 2016 (inclusion period) in five secondary and tertiary hospitals. We present our results of efficacy and safety after 3, 6 and 12 months. Results: N=170 patients were included. N=136, N=106 and N=82 reached 3, 6 and 12 months of follow-up. Eighty-nine patients (52.4%) were male and median age was 47 [34,60] years old. Epilepsy started at 25 [10,44] years old. Sixty-six patients (38.8%) suffered from secondary generalized seizures. Seventy-five patients (56.39%), N=63 (60%) and N=44 (54.32%) were responders at 3, 6 and 12 months, being N=40 (30.07%), N=35 (33.33%) and N=29 (35.8%) seizure free. Adherence was optimal: 92.42%, 96.08% and 97.5% at 3,6, and 12 months respectively. N=19, N=9 and N=5 patients abandoned ESL and N=35 (25.73%), N=13 (12.26%) and N=7 (8.54%) patients reported adverse events. The most frequent was instability. Five adverse events (4.72%) were considered severe (2 hyponatremias, 2 vomiting syndrome, 1 somnolence) with no fatal consequences. Twenty-nine patients (76.32%) at three months, N=19 (67.86%) at six months and N=15 (60%) at twelve months became free of secondary generalization. Conclusions: Our study shows a high tolerability and adherence of ESL. Together with its efficacy, with special remark on the control of secondary generalized seizures, it makes ESL an attractive option as adjuntive treatment of patients with partial onset seizures. Funding: No funding was received in support of this abstract.